After hours:
| Previous Close | 1.1100 |
| Open | 1.1000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0100 - 1.1023 |
| 52 Week Range | 1.0100 - 428.0000 |
| Volume | |
| Avg. Volume | 1,573,698 |
| Market Cap | 4.559M |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1,375.2000 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TipRanksAditxt CEO Clarifies NASDAQ Compliance and Capital Strategy
The latest update is out from Aditxt, Inc. ( (ADTX) ). Amro Albanna, CEO of Aditxt, Inc., recently held an informative stakeholder update and Q&A session to provide transparency and clarity about the company’s direction and strategies. The session addressed key concerns such as NASDAQ compliance misconceptions, capital needs for a microcap company like Aditxt, and the rationale behind recent equity line actions. Albanna emphasized the importance of having access to efficient capital to sustain a
- Business Wire
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
MOUNTAIN VIEW, Calif., October 10, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) ("Appili") has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will be held virtually on Nov
